tbuckley/cabot-search huggingface dataset:
Expansion of Donor NK Cells for Adoptive Immunotherapy in Haploidentical Stem Cell Transplantation: A Phase I–II Study
Authors: Uwe Siegler, Sandrine Meyer-Monard, Simon Jörger, Martin Stern, Andre Tichelli, Alois Gratwohl, Aleksandra Wodnar-Filipowicz, Christian Kalberer
Journal: Blood (2008)
Repetitive Cycles of High-Dose Cytarabine Are Effective for Childhood Acute Myeloid Leukemia (AML): Long Term Outcome of the Children with AML Treated on Two Consecutive Trials of Tokyo Children’s Cancer Study Group.
Authors: Daisuke Tomizawa, Ken Tabuchi, Akitoshi Kinoshita, Ryoji Hanada, Hisato Kigasawa, Ichiro Tsukimoto, Masahiro Tsuchida
Journal: Blood (2005)
Dose escalation with high-dose 3D-conformal radiotherapy (HD-3D-CRT) or low-dose 3D-conformal radiotherapy plus HDR brachytherapy (LD-3D-CRT+HDR-B) for intermediate- or high-risk prostate cancer: Higher PSA control with lower toxicity.
Authors: B. Guix, J. Bartrina, J. Tello, T. Lacorte, I. Henriquez, J. Sole, I. Guix, G. Galdon, M. Espino
Journal: Journal of Clinical Oncology (2011)

82 Background: To report early and late toxicity and preliminary biochemical outcome in in a prospective serie of 445 patients with intermediate- or high-risk clinically localized prostate cancer treated with either HD-3D-CRT or with LD-3D-CRT+HDR-B. Methods: Between 12/1999 and 10/2005, 445 patients (pts) with PSA &gt;10, Gleason score &gt; 6 and/or T2b-T3 N0 M0 prostate cancer entered the study. Pts were prospevtively assigned to one of the two treatment groups: 76 Gy HD-3D-CRT to the prostate in 38 fractions (group 1; 223 patients) or 46 Gy LD-3D-CRT+ 16 Gy HDR-B given in 2 fractions of 8 Gy (group 2, 222 patients), limiting the maximum rectal dose to 85% of the prescribed dose. Both groups were well balanced taking into account patient’s as well as tumors’ characteristics. Toxicities were scored by the EORTC /RTOG morbidity grading scales. Special attention to local, regional or distant recurrence, survival, late effects, PSA and testosterone levels and quality of life was done. Results: All pts completed treatment. None pts included in the group 1 or 2 experienced grade 3 rectal toxicity. 28 pts of group 1 (12.5%) and 6 pts of group 2 (2.7%) developed grade 2 rectal toxicity (rectal bleeding or urgency). 15 pts in group 1 (6.7%) and 3 pts in group 2 (1.3%) developed grade 1 rectal bleeding (less than 2 times/week). In group 1 and 2, 81.8%and 95,9% of pts were free from rectal reactions respectively (p&lt;0.005). Free from failure survival at 5-year was 82.3% and 98.1% respectively (p&lt;0.05) Conclusions: High-dose 3D-EBRT + HDR brachytherapy was a safe and effective method of escalating the dose to the prostate without increasing the risk of late effects. Acute as well as late rectal complications were significantly reduced with the combined treatment, compared with what was observed with high-dose conventional, 3D-conformal radiotherapy. Short-term PSA control rates tends to be better with in the HDR-boosted patients as spected by higher effective dose. No significant financial relationships to disclose.
Important Distinctions Concerning Pharmaceutical Company–Sponsored Meals and Prescribing Patterns
Authors: Ron Cohen
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial
Authors: David T. Yeung, Michael Osborn, Deborah L. White, Susan Branford, Lauren Haswell, Cassandra Slader, Samar Issa, Devendra K. Hiwase, Mark S. Hertzberg, Anthony P. Schwarer, Robin Filshie, Christopher K. Arthur, Yiu Lam Kwan, Cecily J. Forsyth, David M. Ross, Anthony K. Mills, Andrew Grigg, Timothy Hughes, on Behalf Of ALLG
Journal: Blood (2010)
Breast cancer treatment resources and guideline-concordant treatment in Appalachia.
Authors: N. Yao, M. M. Hillemeier, R. T. Anderson
Journal: Journal of Clinical Oncology (2011)

216 Background: Appalachia has poorer cancer outcomes, but little research has been done regarding availability of cancer care resources in this region and how resource availability may relate to cancer outcomes. This study 1) examines associations between radiation therapy resources and receipt of radiotherapy after BCS in counties within Kentucky - a SEER state; and 2) describes spatial patterning of breast cancer treatment resources in all 13 Appalachian states. Methods: For the Kentucky analyses, county-level data from the Area Resource File and SEER registry are analyzed. Bivariate analyses and spatial lag regression using a 6-nearest neighboring counties matrix are conducted. The sample includes stage I or II primary breast cancer patients age 18+ years diagnosed in Kentucky during 2000-2007. The dependent variable is the county-level percentage of patients received BCS without radiation; independent variables include density of radiation therapy providers and facilities and other socioeconomic covariates. For the analyses of entire Appalachian region, descriptive analyses and exploratory spatial data analysis are conducted including 420 Appalachian counties and 644 non-Appalachian counties in 13 states. Results: In Kentucky 16.44% of 17,227 early stage breast cancer patients received BCS without radiation therapy (21.08% in Appalachia versus 14.80% in non-Appalachia, p&lt;0.001). Appalachian Kentucky had significantly fewer radiation oncologists and radiation therapy facilities per capita than non-Appalachian Kentucky. The number of radiation therapy facilities per capita is negatively associated with rates of BCS without radiation when controlling for covariates. Analysis of 13 Appalachian states shows that Appalachian counties, especially in the Central and Southern regions, had significant fewer physicians per capita in Surgery, Anesthesia, Clinical Pathology, and Radiation Oncology. Clustering of scarce breast cancer care resources was observed in Central Appalachia. Conclusions: Appalachian counties, especially in central Appalachia, have fewer breast cancer treatment resources than non-Appalachian counties, and resource availability is associated with cancer health disparities.
Is body mass index associated with patellofemoral pain and patellofemoral osteoarthritis? A systematic review and meta-regression and analysis
Authors: Harvi F Hart, Christian J Barton, Karim M Khan, Henrik Riel, Kay M Crossley
Journal: British Journal of Sports Medicine (2016)

Patellofemoral pain (PFP) occurs frequently, and may be related to patellofemoral osteoarthritis (PFOA). Obesity is associated with increased risk of knee OA. This systematic review involves a meta-regression and analysis to determine the relationship between body mass index (BMI) and PFP and PFOA, and to determine the link between BMI and interventional outcomes.We searched seven electronic databases and reference lists of relevant papers and systematic reviews, for cross-sectional, prospective, human-based observational and interventional studies reporting BMI in individuals with PFP or PFOA compared to healthy controls. Two independent reviewers appraised methodological quality (epidemiological appraisal instrument). Where possible, data from prospective studies were pooled to conduct meta-regression and case-control, and intervention studies to conduct meta-analysis using the following categories: adolescents with PFP, adults with PFP and PFOA.52 studies were included. We found greater BMI in adults with PFP (standardised mean difference: 0.24, 95% CI 0.12 to 0.36) and PFOA (0.73, 0.46 to 0.99) compared to healthy controls, but not in adolescents with PFP (-0.19, -0.56 to 0.18). We also observed statistical trends (p<0.10) towards higher BMI being a predictor for development of PFP in adults (0.34, -0.04 to 0.71). No significant link between BMI and intervention outcomes in adults with PFP was identified.Higher BMI is present in PFP and PFOA, but not in adolescents with PFP.CRD42015024812.
Elevated Preconditioning Serum Levels of C-Reactive Protein Are Associated with Increased Nonrelapse Mortality and Inferior Survival After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Jiri Pavlu, Katayoun Rezvani, Bhuvan Kishore, Rifca Le Dieu, Joydeep Chakrabartty, Aristeidis Chaidos, Edward J Kanfer, Anastasios Karadimitris, Donald H MacDonald, David Marin, Dragana Milojkovic, Farah O'Boyle, Amin Rahemtulla, David Slade, John M Goldman, Jane F Apperley, Richard M Szydlo
Journal: Blood (2011)
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
Authors: Richard S Finkel, Claudia A Chiriboga, Jiri Vajsar, John W Day, Jacqueline Montes, Darryl C De Vivo, Mason Yamashita, Frank Rigo, Gene Hung, Eugene Schneider, Daniel A Norris, Shuting Xia, C Frank Bennett, Kathie M Bishop
Journal: The Lancet (2016)
Barriers to screening and treatment of breast cancer: Data analysis from Edgecombe County.
Authors: M. E. Picton, B. Ramirez, D. Liles, T. R. Sastry, M. Petruzziello
Journal: Journal of Clinical Oncology (2011)

232 Background: Edgecombe County in NC was described as the 3 rd highest location breast cancer mortality according to the Susan G. Komen report (2007). The major issues detected were low education, lack of healthcare providers, and large numbers of uninsured individuals. Our analysis sought to further characterize the circumstances unique to this region and measures to improve mortality. Methods: Between October 2008 and January 2009, 493 surveys were conducted throughout the county. The surveyors randomly approached female residents of Edgecombe County who completed a questionnaire, which was analyzed for this study. Results: Of the total population 354 women were older than age 40. In this group 82.5% had recent mammograms and 79.8% clinical breast examinations. Also, 91.7% had a Primary Physician who recommended mammograms in 85% of the cases. Only 27.1% had family history of breast cancer and, of those, 86.2% were recommended mammograms. Most were educated (58.6%), had low income (76%) and health insurance (87.4%). Nearly equal numbers of Caucasians and African Americans completed the survey (50.6% vs. 47.6%). Just 8.1% had transportation problems and 3.6% were aware of free mammograms in the health department. Statistical analysis by the Fisher’s Exact Test evaluated the relationship between the likelihood of having a screening mammogram and different variables. Women who attended church were more likely to undergo mammograms (p=0.00054), as were women with insurance (p=0.024). Family histories of breast cancer, lack of transportation, low income or deficient education were not significant determinants to obtain a mammogram. A logistical regression model demonstrated that attendance to church and insurance were the two factors statistically significant in terms of obtaining a mammogram. Conclusions: The main issues identified by our analysis were low-income, low health care literacy and lack of awareness regarding breast cancer programs. Our results were discordant with some of the Susan Komen report data, particularly that the majority of participants had a mammogram. Transportation and religious beliefs were not barriers to screening of breast cancer.
FDA Regulation of Neurological and Physical Medicine Devices: Access to Safe and Effective Neurotechnologies for All Americans
Authors: Leigh Anderson, Patrick Antkowiak, Aden Asefa, Amber Ballard, Tushar Bansal, Ayo Bello, Bernard Berne, Kristen Bowsher, Bennett Blumenkopf, Ian Broverman, Mohamad Bydon, Kuo Chao, Peter Como, Karlene Cork, Ann Costello, Kathryn De Laurentis, Angela DeMarco, Heather Dean, John Doucet, Bradley Dworak, Lisa Epperson, Eric Franca, Naz Ghassemian, Chandramallika Ghosh, Anupama Govindarajan, Jay Gupta, Stacie Gutowski, Robert Herrmann, Michael Hoffmann, William Heetderks, Steven Hsu, Daryl Kaufman, Erin Keegan, Gregg Kittlesen, Kevin Khuu, Hyung Lee, Larry Lo, Ian Marcus, Timothy Marjenin, Binoy Mathews, Sanjay Misra, Vivek Pinto, Vesper Ramos, Samuel Raben, Avena Russell, Devjani Saha, Joonil Seog, Christian Shenouda, Myra Smith, Xiaorui Tang, Kelliann Wachrathit, Jaime Waterhouse, Dhanya Williams, Xiaolin Zheng, Carlos Peña
Journal: Neuron (2016)
Predictors of recurrence among patients with breast cancer who achieved a pathologic complete response (pCR) after neoadjuvant systemic chemotherapy.
Authors: M. Chavez-MacGregor, X. Lei, J. K. Litton, A. Melhem, E. A. Mittendorf, F. Meric-Bernstam, A. A. Sahin, V. Valero, G. N. Hortobagyi, A. M. Gonzalez-Angulo
Journal: Journal of Clinical Oncology (2011)

1036 Background: Neoadjuvant systemic therapy (NST) allows the assessment of treatment response. Several studies have demonstrated the association between a pCR and improved outcomes. Although pCR portends a favorable prognosis, some patients with pCR still relapse. We sought to evaluate the prognostic factors associated to disease relapse among breast cancer patients who achieved pCR. Methods: Patients with primary breast cancer treated with NST between 1988−2009 that achieved a pCR were identified. pCR was defined as no evidence of invasive cancer in the breast and ipsilateral axilary lymph nodes. Kaplan-Meier product limit method was used to estimate distant-metastasis-free survival (DMFS), and overall survival (OS); groups were compared with log-rank test. Multivariate Cox proportional hazards models were fit to identify outcome predictors. Results: 749 patients achieved a pCR after NST. Median age was 49 (21−81). At presentation, 4.4%, 62.7% and 32.9% had clinical stage I, II and III respectively; 20.7% had hormone-receptor positive breast cancer, 44.4% HER2-positive, and 34.9% triple-receptor negative tumors. NST included an anthracycline and a taxane in 52.6% of the patients, an anthracycline in 14% and was trastuzumab-based in 31.1%. Breast conservation was performed in 48.7% of the patients and 74.4% of the total cohort received adjuvant radiation therapy. Median follow-up was 35 months (1−258). 5-year DMFS was 93% (95%CI 90−95) and 5-year OS was 96% (95%CI 93−97). Younger age (<50) and clinical stage IIIC were associated with worse DMFS. In the multivariable model, after adjusting for age, stage, tumor subtype, number of lymph nodes removed and adjuvant radiation; we observed that patients >50 years had significantly decreased risk of distant metastasis (HR 0.47; 95%CI .2-.98). Compared to patients with stage I-IIA, those with stage IIIB-C had an increased risk of distant metastasis (HR 3.92; 95%CI 1.54–10), and worse OS (HR 4.75; 95%CI 1.6−14). Conclusions: Patients with pCR after NST have an excellent outcome. However, younger patients and those with stage IIIB and IIIC are more likely to develop distant metastasis.
Efficacy of neoadjuvant cisplatin and oral capecitabine in locally advanced triple-negative breast cancer.
Authors: N. Latif, F. N. Rana
Journal: Journal of Clinical Oncology (2011)

e11512 Background: Triple-negative breast cancer (TNBC) and BRCA associated breast cancer have inherent defect in DNA repair. We conducted a pilot neo-adjuvant trial of cisplatin and oral capecitabine in TNBC patients to see response and toxicity of this regimen. Methods: Sixteen women with stage II and III, TNBC were treated with 4 cycles of neo-adjuvant cisplatin and Capecitabine. After definitive surgery, patients received standard adjuvant treatment as per their treating physicians. Clinical and pathologic responses were assessed, and toxicities were recorded. Results: Sixteen patients with stage II and III, TNBC were enrolled in the study, 12 (75%) were African American and 4 (25%) Caucasian. Six (37.5%) patients completed all 4 cycles, 6 (37.5%) completed 3 cycles and 4 (25%) completed two cycles of chemotherapy. Two (12.5%) of the 16 patients achieved CR and 10 (62.5%) patients had PR. Three patients (18.7%) lost to follow up or taken off study and one (6.25%) had PD. Seven (43.7%) had breast conservation and 5 (31.25%) had mastectomy. Patients who had surgery, two (16.6%) had pathological CR. Seven (43.8%) patients had grade 2 or 3 GI and renal toxicity. Five patients (31%) had grade 1 or 2 hand foot syndrome. Conclusions: TNBC comprise 15% to 20% of breast cancers in US and vast majority is sporadic. TNBC are particularly susceptible to the interstrand cross-linking agents like cisplatin. In this study 2 (16.6%) of patients with TNBC achieved pCR with neo-adjuvant cisplatin and capecitabine. Overall, 75% of the patients had a good response to treatment. These results are consistent with preclinical and recent clinical data showing that TNBC are responsive to cisplatin, but adding oral capecitabine did not improve response rate. However the patient number is small and compliance was poor in this study to draw any conclusions. Cisplatin and oral capecitabine induced responses in patients with TNBC; however there was increased toxicity and also poor patient compliance in this study. Therefore further study with platinum and PARP inhibitor in neo-adjuvant setting is suggested, because in a recent phase II study with PARP inhibitors in metastatic TNBC patients has shown very promising results.
A clinical trial with culturally appropriate video to increase participation of African Americans in cancer clinical trials.
Authors: D. R. Banda, M. Mete, S. M. Swain
Journal: Journal of Clinical Oncology (2011)

159 Background: There is a need to develop patient-level interventions to change attitudes and increase African American (AA) participation in breast cancer clinical trials (CT). This pilot study tested the efficacy of a 15 minute narrative-based video which we created in the first such intervention in AA patients. Methods: This single group study enrolled 88 breast cancer patients in active treatment at a large urban cancer institute. Eligible patients were self-identified AA, ≥ 21 years, and never participated in a CT. The primary outcome was self-reported likelihood to enroll in a therapeutic CT. Participants were interviewed at baseline using an instrument developed specifically to assess attitudes on six trial barriers. An immediate post-test was administered following the video. McNemar’s test for matched pairs was used to assess the change in likelihood to enroll in a CT. Stuart-Maxwell marginal homogeneity test for matched pairs with multi-category outcomes was used to evaluate which attitudes were impacted by the intervention. Results: Patients enrolled October 2010- February 2011 (n =108), 75% female. Age from 31-87 years, mean 61 (SD=12). Patients' likelihood of enrolling in a CT significantly increased post video [OR 19.5, 95% CI: 5.05 – 166.7, McNemar’s χ 2 = 33.39, P &lt;0.001]. Stuart-Maxwell tests showed significant changes in 28 of 30 attitudinal questions post video. Specifically, the video impacted attitudes associated with a concern about the ethical conduct of investigators; the fear of loss of autonomy after signing an informed consent form; worry about being treated poorly as a poor or minority patient; loss of privacy; and the lack of knowledge and awareness of clinical trials. Conclusions: These data demonstrate the overall efficacy of our video and can be extrapolated to a single disease focus. This should have particular benefit for large cooperative group studies including breast cancer trials.
Primary lung sarcoma: A review of 25 cases in a single tertiary institution.
Authors: A. S. Strimpakos, O. Triantaffylou, E. Gini, A. Vassias, K. N. Syrigos
Journal: Journal of Clinical Oncology (2011)

e20528 Background: Primary lung mesenchymal tumours are quite rare occurring in <1% of all lung cancers (LC). Data is limited regarding the pathophysiology, natural history and treatment of these heterogeneous neoplasms. Treatment options are based on experience from other primary sarcomas. Methods: Medical records of 2,560 patients (pts) diagnosed with LC between 2003-2011 were screened. We examined pts’ demographics, clinical data and treatment details Results: 25/2,560 pts (1%) were diagnosed with primary mesenchymal lung tumours. Male:female ratio was 17:8 and median age 63 years (range 21-81). The histological subtypes as reported were: synovial sarcoma (n=9), Ewing’s Sarcoma/PNET (n=3), sarcomatous carcinoma (n=3), mesenchymal tumours/sarcoma (n=3), fibrosarcoma (n=2), malignant fibrous histiocytoma (n=1), leiomyosarcoma (n=1), blastoma (n=1), biphasic sarcoma (n=1) and polymorphic sarcoma (n=1). Immunocytochemistry showed overexpression of vimentin in 23 pts and of CD99 in 8 pts. Commonest presenting symptoms were chest pain (n=11) and dyspnoea (n=10). Performance Status was satisfactory (ECOG 0-1) in most pts (n=17). Smoking history was reported by 17/25 pts. 15 pts presented with advanced disease and were treated with chemotherapy (CT) (group A). 10 pts with initially localised disease (group B) were treated with either surgery (n=8) or radical chemoradiotherapy (CRT) (n=2). 4 pts received adjuvant CT. The commonest first line regimens were CAV (Cyclophosphamide, Doxorubicin, Vincristine) (n=10, 4pts with SD as best response) and platinum based combinations (n=7, best response: 1 PR, 3 SD). Median overall survival (OS) by Kaplan-Meier estimator for group A and group B were 6.5 months (95% CI 0.0-16.2) and 26 months (95% CI 23.8-28.2) respectively, with 2 pts of group A still on CT. Conclusions: Primary lung sarcoma is rare, occurring in approximately 1% of primary LC. OS in advanced disease is limited to less than 1 year. Surgery and radical CRT, when appropriate, are associated with better survival. Platinum agents seem active and warrant further prospective evaluation in this disease.
Sustained Molecular Response with Maintenance Dose of Interferon Alfa After Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia
Authors: Kensuke Usuki, Nozomi Yusa, Akira Hangaishi, Rieko Sekine, Kenshi Suzuki, Shinya Kimura, Arinobu Tojo
Journal: Blood (2012)